| Outcome |
Relative effect
(95% CI) |
Absolute effect
(95% CI)1 |
Certainty of the Evidence
(GRADE) |
Clinical improvement
D28 |
RR: 0.98
(0.83 - 1.15) |
18 fewer per 1000
(from 155 fewer to 136 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Serious
some concerns regarding adequate randomization and selection of the reported results Inconsistency: Not serious
Indirectness: Serious
single study from a single institution therefore results in this population might not be generalizable to other settings Imprecision: Serious
due to low number of events and/or participants
|
| 1 trials
Beltran-Gonzalez J, 2021
69 participants
|
|
Ivermectin
891 per 1,000
(755 - 1000) |
Hydroxychloroquine
909
per 1,000 |
|
Clinical improvement
D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D28 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D60 |
Outcome not yet measured or reported
|
|
All-cause mortality
D28 |
RR: 2.29
(0.48 - 11.02) |
78 more per 1000
(from 32 fewer to 607 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Serious
some concerns regarding adequate randomization, deviation from intended intervention and selection of the reported results. Inconsistency: Not serious Indirectness: Serious
single study from a single institution therefore results in this population might not be generalizable to other settings Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Beltran-Gonzalez J, 2021
69 participants
|
|
Ivermectin
139 per 1,000
(29 - 668) |
Hydroxychloroquine
61
per 1,000 |
|
All-cause mortality
D60 |
Outcome not yet measured or reported
|
|
Viral negative conversion
D7 |
Outcome not yet measured or reported
|
|
Adverse events
|
RR: 0.92
(0.06 - 14.07) |
2 fewer per 1000
(from 28 fewer to 396 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Beltran-Gonzalez J, 2021
69 participants
|
|
Ivermectin
28 per 1,000
(2 - 426) |
Hydroxychloroquine
30
per 1,000 |
|
Serious adverse events
|
RR: 0.92
(0.06 - 14.07) |
2 fewer per 1000
(from 28 fewer to 396 more)
|
Low certainty
Reasons to downgrade
Risk of bias: Not serious Inconsistency: Not serious Indirectness: Not serious
We presume that the adverse event rates and the corresponding relative risks, are similar across diverse settings, therefore not downgraded for indirectness Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm
|
| 1 trials
Beltran-Gonzalez J, 2021
69 participants
|
|
Ivermectin
28 per 1,000
(2 - 426) |
Hydroxychloroquine
30
per 1,000 |
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
